BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced a private placement of 1,734,798 common shares at a price of PLN 12.33 per share for gross proceeds of PLN 21,390,059.34 on May 4, 2021. The transaction will include participation from Ipopema Securities S.A., Investment Arm.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.96 PLN | +0.40% | -0.20% | +16.16% |
05-22 | Synthaverse S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-10 | Synthaverse S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+16.16% | 88.41M | |
-1.62% | 90.85B | |
-1.05% | 39.02B | |
-11.20% | 33.46B | |
+61.85% | 26.38B | |
-20.75% | 14.51B | |
-6.35% | 13.22B | |
-11.42% | 11.65B | |
-47.67% | 10.57B | |
+6.97% | 9.23B |
- Stock Market
- Equities
- SVE Stock
- News Synthaverse S.A.
- BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment Arm